Hims & Hers Health Inc

2026. g. 21. aug. 20:07 UTC

Barclays maintains an Overweight rating on Hims & Hers Health, lowering its price target to $35. Shares are trading higher amid positive market sentiment.

2026. g. 20. aug. 23:11 UTC

Hims & Hers Health shares are lower in after-market hours, with no specific news identified. The broader market sees mixed sentiment amid rising U.S. Treasury yields.

2026. g. 19. aug. 23:06 UTC

Hims & Hers Health Inc. shares are lower in after-market trading following a lawsuit from the FTC alleging deceptive practices regarding user privacy and billing.

2026. g. 18. aug. 19:36 UTC

Hims & Hers Health Inc shares are declining amid an investigation into potential corporate wrongdoing and ongoing legal challenges involving CEO Andrew Dudum.

2026. g. 13. aug. 20:07 UTC

Hims & Hers Health Inc shares are lower amid an investigation into potential corporate wrongdoing related to a Federal Trade Commission lawsuit.

2026. g. 12. aug. 19:41 UTC

Hims & Hers Health Inc. faces scrutiny over cautious peptide outlook and ongoing investigations into customer data sharing, contributing to a decline in shares today.

2026. g. 11. aug. 19:51 UTC

Hims & Hers Health Inc shares are lower amid broader sector declines following a mixed earnings report and concerns over execution risks.

2026. g. 10. aug. 23:41 UTC

Hims & Hers Health reported a net loss of $86.3 million in Q2, contributing to a decline in share price during after-market trading.

2026. g. 7. aug. 19:26 UTC

Hims & Hers Health Inc. shares are trading higher, reflecting strong intraday momentum, despite a slight pullback from earlier session highs amid falling Treasury yields.

2026. g. 6. aug. 19:16 UTC

Hims & Hers Health is under investigation amid ongoing legal scrutiny. Shares are lower today despite a significant investment and the launch of the Hers App.

2026. g. 4. aug. 19:22 UTC

Hims & Hers Health is higher as an investigation into potential claims is announced, following a lawsuit over customer medical information sharing.

2026. g. 3. aug. 23:41 UTC

Hims & Hers Health shares are higher in after-market trading, following positive growth insights despite facing a lawsuit from the Federal Trade Commission.

2026. g. 31. jūl. 19:36 UTC

Hims & Hers Health Inc is trading higher amid social media discussions about potential undervaluation, despite facing a lawsuit over user health data practices.

2026. g. 30. jūl. 20:11 UTC

Hims & Hers Health Inc shares are higher today amid high trading volume. Broader economic data showed mixed signals, contributing to market volatility.

2026. g. 29. jūl. 23:16 UTC

Hims & Hers Health shares declined in after-market trading amid legal challenges from the FTC over alleged privacy violations and a securities fraud investigation.

2026. g. 28. jūl. 23:41 UTC

Hims & Hers Health shares declined in after-market trading, remaining near the lower end of their one-month range amid broader market pressures from Asian tech losses.

2026. g. 27. jūl. 20:03 UTC

Hims & Hers Health shares rise amid FDA committee's endorsement of peptides, seen as a significant step toward market access for treatments.

2026. g. 24. jūl. 23:16 UTC

Hims & Hers Health Inc. shares rose after-hours following positive votes from an FDA/HHS panel on six peptides, with a final decision expected in up to 12 months.

2026. g. 23. jūl. 23:26 UTC

Hims & Hers Health Inc shares are higher after an FDA advisory panel recommended easing restrictions on a popular peptide and Canaccord reiterated a Buy rating.

2026. g. 22. jūl. 23:16 UTC

Hims & Hers Health shares declined to about $31.66 after mixed options sentiment, with calls outpacing puts amid lighter trading volume.

2026. g. 21. jūl. 17:31 UTC

Hims & Hers Health Inc shares are declining amid an investigation into potential wrongdoing and concerns over FDA approval of key peptides.

2026. g. 20. jūl. 18:37 UTC

Hims & Hers Health Inc. is trading higher amid broader market dynamics, despite earlier pulling back from a session high.